Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aveanna Healthcare Holdings (AVAH) EBITDA (2020 - 2026)

Aveanna Healthcare Holdings (AVAH) has disclosed EBITDA for 6 consecutive years, with $53.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA rose 57.49% year-over-year to $53.6 million, compared with a TTM value of $231.2 million through Sep 2025, up 87.49%, and an annual FY2024 reading of $149.4 million, up 651.75% over the prior year.
  • EBITDA was $53.6 million for Q3 2025 at Aveanna Healthcare Holdings, down from $80.0 million in the prior quarter.
  • Across five years, EBITDA topped out at $80.0 million in Q2 2025 and bottomed at -$456.4 million in Q3 2022.
  • Average EBITDA over 5 years is -$12.9 million, with a median of $28.8 million recorded in 2021.
  • The sharpest move saw EBITDA crashed 1694.99% in 2023, then surged 144.56% in 2024.
  • Year by year, EBITDA stood at $18.3 million in 2021, then plummeted by 1214.39% to -$204.5 million in 2022, then surged by 114.33% to $29.3 million in 2023, then skyrocketed by 56.25% to $45.8 million in 2024, then increased by 17.07% to $53.6 million in 2025.
  • Business Quant data shows EBITDA for AVAH at $53.6 million in Q3 2025, $80.0 million in Q2 2025, and $51.8 million in Q1 2025.